ANKRD6 and non-small cell lung carcinoma: Thus far, most studies consider DIVERSIN to be a pro-tumour factor, as it enhances tumour proliferation and invasion in a variety of malignancies, such as non-small cell lung cancer, colorectal carcinoma, breast cancer and glioma [17,18,19,20].